Related by context. All words. (Click for frequent words.) 76 Adjuvant Therapy 76 Irinotecan 76 Adjuvant Treatment 75 Metastatic Prostate Cancer 75 Adjuvant Chemotherapy 74 Bevacizumab 74 Advanced Prostate Cancer 74 Hormone Refractory Prostate Cancer 74 TO AVOID PREGNANCY WHILE 74 Improved Survival 74 Paraplatin ® 74 Improves Survival 74 5 Fluorouracil 73 Gemcitabine 73 Renal Cell Carcinoma 73 Trastuzumab 73 Previously Untreated 73 Pemetrexed 73 Peginterferon 73 sorafenib Nexavar 73 Cyclophosphamide 73 Patients Receiving 73 ZACTIMA 73 Prolongs Survival 72 Capecitabine 72 Meets Primary Endpoint 72 Antitumor Activity 72 ritonavir boosted 72 Patients Treated 72 Chemoradiation 72 Lenalidomide 72 Degarelix 72 Sorafenib 72 Allogeneic 72 Patients Treated With 72 Melphalan 72 cisplatin gemcitabine 72 Bivalirudin 72 Breast Cancer Recurrence 72 Pooled Analysis 72 Survival Benefit 72 Advanced Melanoma 72 Treated Patients 72 metastatic malignant 72 Node Positive 71 alfa 2a 71 Bosutinib 71 Study Evaluating 71 gefitinib Iressa 71 Oral Fingolimod 71 Improves Outcomes 71 Neoadjuvant Chemotherapy 71 Malignant Melanoma 71 Platinol ® 71 HER2 Positive Breast Cancer 71 Pertuzumab 71 mycophenolate mofetil 71 Newly Diagnosed Multiple Myeloma 71 dasatinib Sprycel 71 FASLODEX 71 Dasatinib 71 Sipuleucel T 71 Monotherapy 71 Heart Failure Patients 71 Anthracycline 71 Localized Prostate Cancer 71 R lenalidomide 71 Radioimmunotherapy 71 Pegylated Interferon 71 Doxil ® 71 Follicular Lymphoma 71 Abciximab 71 Epirubicin 71 Severe Sepsis 71 Erlotinib 71 bevacizumab Avastin ® 71 Azacitidine 71 Previously Treated 71 neoadjuvant treatment 71 Exemestane 71 Gastric Cancer 71 Temsirolimus 71 pegylated liposomal doxorubicin 71 Metastatic Colorectal Cancer 71 Anastrozole 70 dasatinib Sprycel ® 70 erlotinib Tarceva ® 70 Phase IIb Trial 70 Unfractionated Heparin 70 Improve Survival 70 Fulvestrant 70 Cardiotoxicity 70 thalidomide Thalomid 70 alpha 2a 70 Fluorouracil 70 estramustine 70 Naive Patients 70 Autologous Stem Cell Transplantation 70 Patients Undergoing 70 Colorectal Cancer Patients 70 Randomized Study 70 Glatiramer Acetate 70 AVASTIN 70 Immunotherapeutic 70 neoadjuvant 70 Kidney Transplant Patients 70 Pegylated Liposomal Doxorubicin 70 Combination Treatment 70 Combination REOLYSIN R 70 capecitabine Xeloda 70 Metastatic Renal Cell Carcinoma 70 Investigational Agent 70 adalimumab Humira 70 Disease Progression 70 Chronic Hepatitis C 70 Androgen Deprivation Therapy 70 Well Tolerated 70 relapsed MM 70 Nilotinib 70 Low Dose 70 Demonstrates Significant 70 Taxotere ® 70 Relapsing Multiple Sclerosis 70 Aflibercept 70 Bevacizumab Avastin 70 Randomized Phase II 70 Femara letrozole 70 Pazopanib 70 Phase III Clinical Trial 70 Combination Therapy 69 Lung Cancer Patients 69 Fludarabine 69 trastuzumab Herceptin 69 Neulasta ® 69 metastatic renal cell carcinoma 69 cetuximab Erbitux R 69 Fixed Dose 69 Medoxomil 69 Tipranavir 69 Natalizumab 69 Metastatic Melanoma 69 chemoradiation therapy 69 Xeloda ® 69 Soft Tissue Sarcoma 69 Mycophenolate Mofetil 69 pertuzumab 69 Intravitreal 69 Pulmonary Arterial Hypertension 69 Gefitinib 69 Eculizumab 69 paclitaxel Taxol 69 Phase III Trial 69 Clinical Outcome 69 Double Blind Randomized 69 Cinacalcet 69 metastatic castration resistant 69 Pivotal Phase III 69 Fondaparinux 69 Phase III Trials 69 Interferon Beta 69 Unresectable 69 Tyrosine Kinase Inhibitor 69 Bortezomib 69 Complicated Skin 69 FEMALES SHOULD BE ADVISED 69 ACE Inhibitors 69 Hepatocellular Carcinoma 69 Hormone Receptor Positive 69 Peginterferon Alfa 2a 69 Plus Ribavirin 69 HER2 Positive 69 PEG IFN 69 Placebo Controlled Trial 69 Ozarelix 69 Glufosfamide 69 paclitaxel Taxol R 69 NSABP B 69 Single Dose 69 Phase 2b Study 69 FOLFOX6 69 Invasive Breast Cancer 69 Zoledronic Acid 69 goserelin 69 Breast Cancer Patients 69 Radical Prostatectomy 69 receptor tyrosine kinase inhibitor 69 Controlled Trial 69 Investigational Drug 69 LHRH receptor positive 69 fallopian tube carcinoma 69 Lung Cancer Trial 69 neoadjuvant chemotherapy 69 5 FU leucovorin 69 Rheumatoid Arthritis Patients 69 Is Well Tolerated 69 MAGE A3 ASCI 69 Decitabine 69 Taxotere docetaxel 69 Prospective Randomized 69 Novel Oral 69 Advanced Renal Cell 69 APTIVUS R 69 II Clinical Trial 69 Acute Ischemic Stroke 69 See CLINICAL PHARMACOLOGY 69 Dual Antiplatelet Therapy 68 Posaconazole 68 Relapsed Refractory 68 Percutaneous Tibial Nerve Stimulation 68 bevacizumab Avastin 68 SPRYCEL ® 68 Radiofrequency Ablation 68 chemoradiotherapy 68 GW# [003] 68 recurrent glioblastoma multiforme 68 Pharmacokinetic Study 68 Antiplatelet 68 cinacalcet 68 Myeloma Patients 68 Prostate Cancer Patients 68 Elderly Patients 68 Fludara ® 68 epirubicin 68 Statistically Significant 68 Castration Resistant Prostate Cancer 68 Anti Tumor 68 Oxaliplatin 68 Randomized Clinical Trial 68 Neupogen ® 68 Mitoxantrone 68 Safinamide 68 5 fluorouracil leucovorin 68 Preclinical Study 68 Tocilizumab 68 Dose Ranging Study 68 Postmenopausal 68 Infliximab 68 nab paclitaxel 68 Carotid Stenting 68 Vidaza azacitidine 68 Knee Osteoarthritis 68 etanercept Enbrel 68 letrozole Femara 68 Randomized Double Blind 68 rituximab Rituxan 68 assessing T DM1 68 Vandetanib 68 Cilostazol 68 epoetin alpha 68 platelet inhibitor 68 sunitinib Sutent ® 68 Tacrolimus 68 docetaxel Taxotere ® 68 Torisel 68 Gemzar ® 68 Phase 2b Clinical Trial 68 metastatic GIST 68 Statin Therapy 68 Platelet Inhibition 68 mitoxantrone plus 68 Adalimumab 68 Anti Tumor Activity 68 Cutaneous T 68 Benign Prostatic Hyperplasia 68 Nebulized 68 Anti TNF 68 Stent Thrombosis 68 docetaxel cisplatin 68 Protease Inhibitor 68 Pivotal Phase 68 Boosts Survival 68 Epoetin Alfa 68 alfa 2b 68 Prostate Cancer Treatment 68 APTIVUS 68 Nexavar sorafenib 68 Camptosar ® 68 ACTEMRA TM 68 Adefovir 68 JAK Inhibitor 68 FOLFOX4 68 Pharmacokinetics PK 68 Interferon Alfa 68 PEGylated anti 68 Myelodysplastic Syndromes 68 DAPT 68 standard chemotherapy regimen 68 FUSILEV enhances 68 Metastatic Breast Cancer 68 Trial Evaluating 68 neoadjuvant therapy 68 Interferon beta 1a 68 Aurora Kinase 68 Pegylated 68 Venous Thromboembolism 68 docetaxel Taxotere 68 stage IIIB 68 Sprycel dasatinib 68 Amrubicin 68 Epidermal Growth Factor Receptor 68 Peginterferon alfa 2b 68 Dose Escalation 68 Renal Cancer 68 Leucovorin 68 Quinamed 68 Bicalutamide 68 Initiate Phase 68 Stent Implantation 67 abacavir Ziagen 67 Faslodex 67 mRCC 67 Oral Mucositis 67 Pfizer Sutent 67 Xelox 67 Granulocyte Colony Stimulating Factor 67 Appears Safe 67 lapatinib Tykerb 67 bevacizumab Avastin R 67 Hsp# Inhibitor 67 Cloretazine 67 Acute Myocardial Infarction 67 Versus Placebo 67 EGFR TKI 67 Mantle Cell Lymphoma 67 Darunavir 67 cediranib 67 Antiangiogenic 67 Breast Cancer Treatment 67 Kinase Inhibitor 67 Randomized Evaluation 67 imatinib Gleevec ® 67 ixabepilone 67 Herceptin trastuzumab 67 BARACLUDE ® 67 Demonstrates Efficacy 67 tiuxetan 67 Hormone Therapy 67 Demonstrates Potent 67 Tarceva TM 67 Paclitaxel Carboplatin 67 Prospective Randomized Trial 67 Subgroup Analysis 67 Pivotal Trial 67 gemcitabine Gemzar 67 Hepatotoxicity 67 Denufosol 67 dual endothelin receptor antagonist 67 TNF Tumor Necrosis Factor 67 Etanercept 67 Proven Effective 67 CT Angiography 67 Pioglitazone 67 Predict Response 67 Brain Metastases 67 corifollitropin alfa 67 Receives Orphan Drug Designation 67 temsirolimus 67 IN PATIENTS WITH 67 Randomized Phase 67 Clopidogrel 67 Eluting Stent 67 Infarct 67 Investigational Compound 67 cell lymphoma CTCL 67 Cardiovascular Events 67 Diabetic Neuropathy 67 Ranolazine 67 metastatic colorectal 67 Teva Provides Update 67 Infected Patients 67 NDA Submission 67 YONDELIS 67 PKC# 67 Node Negative 67 Cetuximab 67 Tyrosine Kinase Inhibitors 67 ZOLINZA 67 Patient Outcomes 67 Aliskiren 67 Contrast Agents 67 Romiplostim 67 clodronate 67 Fewer Side Effects 67 Abiraterone Acetate 67 Bucindolol 67 Renal Insufficiency 67 Insulin Glargine 67 FDA Approvals 67 recurrent NSCLC 67 Platinol ® cisplatin 67 chemotherapy cisplatin 67 Xeloda capecitabine 67 Betaferon R 67 Acute Coronary Syndromes 67 recurrent GBM 67 relapsing multiple sclerosis 67 sunitinib Sutent 67 decitabine 67 metastatic gastric 67 evaluating tivozanib 67 anastrozole Arimidex 67 Telbivudine 67 Newly Diagnosed Patients 67 Tiotropium 67 Liver Failure 67 cyclophosphamide methotrexate 67 Clinical Trial Results 67 hormone refractory metastatic prostate 67 Refractory Hodgkin Lymphoma 67 vorinostat 67 IL# PE#QQR 67 Immunosuppression 67 Relapsing Remitting Multiple Sclerosis 67 unfractionated heparin UFH 67 Sanofi Aventis Taxotere 67 Taxotere chemotherapy 67 finasteride Proscar 67 gastrointestinal stromal tumors GIST 67 FIRMAGON 67 ® lenalidomide 67 Docetaxel 67 fosbretabulin 67 Ibritumomab Tiuxetan 67 Anticancer Activity 67 Phase 2b Trial 67 Long Term Efficacy 67 Pivotal Study 67 Myelofibrosis 67 STRIDE PD 67 Thromboembolism 67 adjuvant radiotherapy 67 Chronic Sinusitis 67 FOLFIRI 67 Aptivus ® 67 fluorouracil 67 Severe Asthma 67 sorafenib tablets 67 nilotinib Tasigna 67 HER2 positive metastatic breast 67 Uterine Fibroid Embolization 67 dalteparin 67 flutamide 67 Moxifloxacin 67 Metastatic Pancreatic Cancer 67 Carvedilol 67 Sandostatin R 67 Prostate Cancer Vaccine 67 Enlarged Prostate 67 metastatic castrate resistant 67 Shows Statistically Significant 67 Zarnestra 67 Intravesical 67 Kinase Inhibitors 67 Ambrisentan 67 galiximab 66 Gastrointestinal Stromal Tumors 66 Deforolimus 66 Carcinoma 66 Fracture Risk 66 Stent Restenosis 66 Breast Cancers 66 Demonstrates Positive 66 FDA APPROVES 66 Temodar ® 66 Initiates Clinical Trial 66 Preclinical Data 66 ORENCIA ® 66 NAVISTAR R 66 Initiate Clinical Trial 66 Double Blind Placebo 66 Treatment Naive Patients 66 PEGylated interferon beta 1a 66 Dapagliflozin 66 Elotuzumab 66 raloxifene Evista 66 REVLIMID R 66 ibandronate 66 Anticancer Agent 66 Romidepsin 66 concurrent chemoradiation 66 vincristine doxorubicin 66 luteinizing hormone releasing 66 Corticosteroid 66 Boceprevir 66 REVLIMID ® 66 Peg IFN 66 Successfully Completes Phase 66 Bladder Cancer 66 Chemotherapy Regimen 66 CLARITY TIMI 66 Gliadel Wafer 66 pegfilgrastim 66 Regimens 66 NMIBC 66 adriamycin 66 Acute Pancreatitis 66 Parathyroid Hormone 66 myelodysplastic myeloproliferative diseases 66 rFSH 66 Treatment Naive HIV 66 Cyclooxygenase 2 66 fallopian tube cancers 66 Rheumatoid Arthritis Drug 66 Anticancer Drug 66 Multiple Myeloma Patients 66 Cardiovascular Outcomes 66 docetaxel chemotherapy 66 Study Showed 66 Completes Patient Enrollment 66 Alemtuzumab 66 Non Responders 66 Cisplatin 66 Granted Orphan Drug 66 Toremifene 66 ergot derivatives 66 Prostate Cancer Progression 66 Ovarian Cancer Patients 66 sunitinib malate 66 Coronary Artery Bypass Graft 66 cetuximab Erbitux 66 erlotinib Tarceva 66 Hemodialysis Patients 66 stage IIIb IV 66 Expanded Indication 66 Patency 66 Immunomodulatory 66 Tigecycline 66 trabectedin 66 First Patient Dosed 66 lexidronam injection 66 Placebo Controlled Study 66 atazanavir sulfate 66 Bosentan 66 Tumor Response 66 dexamethasone Decadron 66 Mg Uk 66 Bone Metastases 66 B Cell Lymphoma 66 Mg Usa 66 ribavirin RBV 66 Novel Inhibitor 66 Interferon alfa 66 efalizumab 66 Nitazoxanide 66 alfuzosin 66 Mitomycin C 66 Chronic Myeloid Leukemia 66 Multicenter Trial 66 Ranibizumab 66 Bendamustine 66 Myocet 66 Pediatric Patients 66 PEGINTRON TM 66 Bezielle 66 nonmetastatic 66 Aortic Stenosis 66 TroVax ® 66 STENT 66 Navelbine ® 66 Schizophrenia Treatment 66 Selective Internal 66 Postmenopausal Osteoporosis 66 Embolization 66 Polymerase Inhibitor 66 Treatment Naïve Patients 66 Zoledronic acid 66 Pivotal Clinical Trial 66 CALGB 66 Oral Cladribine 66 demonstrated antitumor activity 66 Flu Cy 66 Estrogen Receptor 66 biliary tract cancer 66 Breast Tumors 66 imatinib Gleevec 66 Randomized Double Blind Placebo 66 candesartan cilexetil 66 Treat Anemia 66 Androgen Deprivation 66 Blinatumomab 66 plus COPEGUS 66 PSMA ADC 66 PEGylated Fab fragment 66 Advaxis Phase 66 Prophylactic Treatment 66 Montelukast 66 Skeletal Muscle 66 Hydroxyurea 66 carboplatin paclitaxel 66 Ziprasidone 66 Achieves Primary Endpoint 66 Progressive Multifocal Leukoencephalopathy 66 Lung Cancer Drug 66 radiotherapy RT 66 infusional 66 Fingolimod 66 fulvestrant 66 preoperative chemotherapy 66 Chronic Heart Failure 66 Myelodysplastic Syndrome MDS 66 Shows Efficacy 66 Rituximab 66 Solid Tumors 66 IRESSA 66 Golimumab 66 Juvenile Idiopathic Arthritis 66 Obese Patients 66 Advanced Pancreatic Cancer 66 Chronic Lymphocytic Leukemia 66 Combo Therapy 66 BCIRG 66 exemestane Aromasin 66 External Beam 66 Stereotactic Body Radiation Therapy 66 metastatic androgen independent 66 epoetin beta 66 debulking surgery 66 Velcade bortezomib 66 hyperplasia BPH 66 Idiopathic Pulmonary Fibrosis 66 fluvastatin 66 transarterial 66 leukotriene receptor antagonist 66 Pralatrexate 66 Valsartan 66 external beam radiotherapy 66 Adenoma 66 Copegus ribavirin 66 Lung Cancer Survival 66 Disease Modifying 66 ABVD 66 Surgical Treatment 66 Efficacious 65 Controlled Study 65 Taxane 65 melphalan prednisone 65 Endometrial Cancer 65 Liver Metastases 65 Advanced Ovarian Cancer 65 Septic Shock 65 paroxetine Paxil 65 mapatumumab 65 Relapsed Multiple Myeloma 65 LENALIDOMIDE 65 unresectable tumors 65 BEACOPP 65 aripiprazole Abilify 65 Adjuvant 65 Recombinant Human 65 Drug Candidate 65 DOXIL 65 Cholesterol Lowering Drug 65 Unstable Angina 65 Randomised 65 ribavirin USP 65 paclitaxel cisplatin 65 registrational Phase 65 Lung Cancers 65 Slow Progression 65 Percutaneous Coronary Intervention 65 Treatment Regimen 65 Transdermal Patch 65 YERVOY 65 TLK# 65 Adjunctive 65 Tolerability 65 Psoriasis Drug 65 Lupus Nephritis 65 pan HDAC inhibitor 65 Metastatic 65 Protease Inhibitors 65 Inhaled Corticosteroids 65 Lubiprostone 65 refractory chronic lymphocytic 65 paclitaxel poliglumex 65 Taxotere R 65 Tanespimycin 65 Median PFS 65 Demonstrated Significant 65 Prognostic Value 65 Randomized Phase III 65 Diabetic Patients 65 Enoxaparin 65 FDA Okays 65 Plaque Psoriasis 65 Gemzar gemcitabine 65 zoledronate 65 XELOX 65 gemcitabine cisplatin 65 essential thrombocythemia ET 65 icatibant 65 Epratuzumab 65 Postmenopausal Women 65 ARIXTRA R 65 Abatacept 65 trastuzumab Herceptin ® 65 multikinase inhibitor 65 Ixempra 65 Clinical Trial Evaluating 65 CYT# potent vascular disrupting 65 Overactive Bladder 65 Cell Lymphoma 65 efavirenz EFV 65 Treatment Naive 65 Bone Mineral Density 65 vandetanib 65 Clinical Trial Data 65 cilengitide 65 intravesical infusion therapy 65 Taxol ® 65 Anticancer Drugs 65 Stomach Cancer 65 Leukemias 65 ErbB2 positive 65 Vaginal Gel 65 Alkeran 65 HMG CoA reductase inhibitors 65 Sirolimus Eluting Stent 65 alefacept 65 J Am Coll 65 BRIM2 65 Avastin bevacizumab 65 relapsed ovarian cancer 65 XYOTAX TM 65 Renal Cell Carcinoma RCC 65 colesevelam HCl 65 SPIRIVA ® 65 mitomycin 65 Vidaza ® 65 Revlimid lenalidomide 65 Left Ventricular Dysfunction 65 mycophenolic acid 65 beta 1a 65 Minimally Invasive Treatment 65 androgen suppression 65 Glioma 65 postoperative chemotherapy 65 temsirolimus Torisel 65 Fluconazole 65 infliximab Remicade 65 treat benign prostatic 65 PEG interferon 65 Less Invasive 65 Breast Density 65 malignant ascites 65 Prostate Cancers 65 Phase 2a Trial 65 HCV Protease Inhibitor 65 gemtuzumab ozogamicin 65 Phase 2a Clinical Trial 65 Hepatitis C Patients 65 Antiplatelet Therapy 65 plus prednisone 65 Carboplatin 65 cancer mCRC 65 Phase Ib Clinical Trial 65 irinotecan chemotherapy 65 Disease Modification 65 Kidney Transplant Recipients 65 Rectal Cancer 65 Atypical Hemolytic Uremic Syndrome 65 Non Alcoholic Steatohepatitis 65 Pafuramidine 65 Recurrent Breast Cancer 65 Peginterferon Alfa 2b 65 Zorbtive TM 65 Tezampanel 65 Prospective Multicenter 65 Tesamorelin 65 phase IIIb 65 Phase III Clinical Trials 65 Efficacy Trial 65 SUPPRELIN R LA 65 Trastuzumab Herceptin 65 oxaliplatin Eloxatin 65 Renal Impairment 65 Vidofludimus 65 Anti VEGF 65 Initiates Enrollment 65 IMiDs ® compound 65 Cetuximab Erbitux 65 Procoralan 65 Brentuximab Vedotin SGN 65 Nesiritide 65 liposomal amphotericin B 65 CCX# B 65 Risedronate 65 Hycamtin ® 65 ara C 65 achieved CCyR 65 HCV Genotype 65 Diffuse Large B 65 RENAL 65 Calcium Acetate 65 Therapy Reduces 65 Initiates Phase III 65 Antigen Specific 65 Aggressive Prostate Cancer 65 Gout Drug 65 IND Application 65 prostate cancer mCRPC 65 HuMax EGFr 65 MYCAMINE 65 First Patient Enrolled 65 ST Segment Elevation 65 Fluticasone 65 Treatment Reduces 65 Oral Anticoagulant 65 Coronary Angiography 65 Pegylated interferon 65 Randomized Trials 65 Osteoporosis Drug 65 Relapsed 65 doxorubicin cyclophosphamide 65 Roche Xeloda 65 Investigational Treatment 65 Treatment Naïve 65 Phase IIb Clinical Trial 65 bacillus Calmette Guerin 65 Elagolix 65 familial amyloidotic polyneuropathy FAP 65 Afatinib 65 Antiviral Activity 65 J Clin 65 Dabigatran 65 eribulin mesylate 65 Adjunctive Therapy 65 Daptomycin 65 MGd 65 anthracycline taxane 65 glatiramer acetate 65 Patient Enrollment 65 oral antidiabetic medication 65 Elitek 65 Demonstrates Potential 65 Blood Pressure Drug 65 selective modulator 65 Enzyme Replacement Therapy 65 prednisone prednisolone 65 prostate cancer HRPC 65 Doxorubicin 65 BARACLUDE R 65 Hematological Malignancies 65 Contrast Agent 65 palifermin 65 zoledronic acid Zometa 65 chemotherapy FOLFOX 65 Accelerated Partial Breast Irradiation 65 Lacosamide 65 Tarceva erlotinib 65 Renal Artery 65 leukemia AML 65 PRN FDA Approves 65 Bazedoxifene 65 Ovidrel 65 Drug Shows Promise 65 Enzastaurin 65 Phase Ib II 65 Intravenous CP 65 Fungal Infections 65 HDAC Inhibitor 65 Levoleucovorin 65 somatostatin analog 65 Imatinib mesylate 65 trastuzumab DM1 65 venlafaxine Effexor 65 Meta Analysis 65 Cardiac Resynchronization 65 Demonstrates Sustained 65 oral prodrug 65 PEGASYS ® 65 Dutasteride 65 nadolol 65 Everolimus 65 Recurrent Ovarian Cancer 65 pancreatic adenocarcinoma 65 pregabalin Lyrica 65 FOLPI 65 NICE Recommends 64 Drug Combo 64 Significantly Improved 64 Kinoid 64 Atypical Antipsychotics 64 Taxol paclitaxel 64 prostate cancer CRPC 64 denileukin diftitox 64 Pelvic Organ Prolapse 64 Submits NDA 64 prucalopride 64 tipranavir 64 Hematopoietic 64 Liposomal 64 Advagraf 64 Angiotensin Converting Enzyme 64 Oral Formulation 64 Prophylaxis 64 #mg/#mg 64 Sirolimus Eluting 64 TRANSFORMS 64 adalimumab 64 cetuximab Erbitux ® 64 ARIMIDEX 64 TAXOTERE R 64 Copegus ® 64 Interferon Alpha 64 pan histone deacetylase 64 Lipid Lowering 64 GOUT 64 Osteoporosis Drugs 64 ALN HPN 64 Silodosin 64 boosted protease inhibitor 64 Nymox NX 64 alpha blocker 64 Lamotrigine 64 Annamycin 64 Tasigna nilotinib 64 colorectal carcinoma 64 Randomized Comparison 64 locoregional recurrence 64 trastuzumab Herceptin R 64 lenalidomide Revlimid 64 Folfox 64 chemoradiation 64 interferon ribavirin 64 non peptidic protease 64 Malignant Glioma 64 abacavir lamivudine 64 Bisphosphonate 64 Multicenter Randomized 64 Recurrent Glioblastoma 64 Bayer Onyx 64 pegylated interferon alfa 2b 64 plus dexamethasone 64 adjuvant radiation 64 Confirmatory Phase 64 Myelodysplastic Syndrome 64 adefovir dipivoxil 64 ximelagatran 64 bortezomib Velcade R 64 corticosteroid dexamethasone 64 Cytarabine 64 Invasive Fungal Infections 64 sitaxsentan 64 invasive candidiasis 64 Angiogenic 64 CIMZIA TM certolizumab pegol 64 octreotide 64 certolizumab 64 Fast Track Status 64 Tumor Necrosis Factor 64 Xanafide 64 immunomodulatory therapy 64 q#h 64 Metastatic Disease 64 Prostatic 64 metastatic hormone refractory 64 oral rivaroxaban 64 Randomized Double blind 64 trabedersen 64 mertansine 64 azacitidine 64 Myocardial Perfusion Imaging 64 cabazitaxel 64 Restenosis 64 Secondary Hyperparathyroidism 64 Systemic Delivery 64 Raloxifene STAR 64 CIMZIA TM 64 Phospholipase A2 64 PROSTVAC VF 64 Vinorelbine 64 daunorubicin 64 Autologous 64 liposome injection 64 REYATAZ ® 64 Benign Prostatic Hyperplasia BPH 64 Endometrial 64 Phase IIIb clinical 64 insulin glulisine 64 Etoposide 64 teriflunomide 64 Novel Compound 64 Microalbuminuria 64 Antiviral Therapy 64 Percutaneous Transluminal Coronary Angioplasty 64 Fludara 64 Noxafil 64 recurrent prostate cancer 64 Glaxo Tykerb 64 Imatinib 64 Signaling Pathway 64 Vicriviroc 64 Improve Outcomes 64 Cell Lymphoma CTCL 64 antiangiogenic therapy 64 BENICAR HCT 64 aspirin clopidogrel 64 By JENNIFER LEARN